Nano Nano – Trevor Morin and William Dunbar of Two Pore Guys, Inc. – Nanotechnology Opens New Opportunities in Research

Trevor Morin, PhD, CSO biochemistry, and William Dunbar, PhD, cofounder and acting CEO, of Two Pore Guys, Inc., provide an interesting overview of nanotechnology as it applies to scientific advances.

Morin and Dunbar's company, Two Pore Guys, Inc., is literally transforming human and environmental health by bringing nanotechnology and precision science together to detect and quantify biomolecular targets.

The science and technology entrepreneurs discuss their products and advances in nanotechnology in regard to agriculture, human, and animal use cases. They discuss nanopores, which are sort of like tiny gateways that allow only one molecule to proceed through at a time. As they explain, this 'passing through' process allows for information to be gathered in detail. The sweet spot for their technology, as they explain, is identifying pathogens based on their DNA or RNA-specific sequence.

Specifically, Morin and Dunbar's, Two Pore Guys, Inc. is a team of biochemists and engineers who work together to develop groundbreaking technology. Their innovative single-molecule-sensing platform can provide the precision, accuracy, and sensitivity of reference lab equipment while saving time and money.

The scientific pathology tech guys elaborate on how they solve problems built into field-deployable products. With singe molecule counting using an electrical output they find that their accuracy is heightened, with extremely sensitive reagents. Their breakthrough technology allows for superior detection of multiple infectious agents. Their device differentiates among a whole suite of infectious diseases with improved time performance. Additionally, as they explain, the Two Pore Guys' platform eliminates the need for complex instrumentation and chemistries, and again, is more cost effective than traditional methods used currently. And in regard to quantifying genetic variants, their outstanding platform can detect and quantify cancer variants from liquid biopsies with the precision of droplet digital PCR, and again, at a faster rate and reduced cost than traditionally used methods.

The science innovators discuss their timetable for revealing more of their product line. As they explain, their beta unit will be available in less than two years. Morin and Dunbar are excited about the possibilities and their continual advancement of products that can enhance scientific and medical innovation.